Pegvaliase: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Pegvaliase. Educational only — not medical advice.
Labeled uses
PALYNZIQ is indicated to reduce blood phenylalanine concentrations in adult and pediatric patients 12 years of age and older with phenylketonuria (PKU) who have uncontrolled blood phenylalanine concentrations greater than 600 micromol/L on existing management.
Source: FDA labeling via NIH DailyMed (set 6dba844a…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.